Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Würselen – page 50

1 367 clinical trials in Würselen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Würselen at a glance
1 367
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 367 trials in Würselen

Open in trial search

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Crohn's disease

Not yet recruiting

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:UZ Leuven

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Celea Therapeutics Inc.

Varicella+5

Not yet recruiting

Immune response and safety of investigational MMRV vaccine (GSKVX000000025896) drug combination compared with standard MMRV vaccine in healthy children 15 months to 6 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Propranolol Hydrochloride
  • Sponsor:Radboud universitair medisch centrum Stichting

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Würselen

What the registry says about research in the country

01 Urological Oncology

Innovative research focusing on non-muscle invasive bladder cancer, evaluating combination therapies including immunotherapy approaches. These trials aim to improve treatment outcomes and reduce recurrence rates.

  • BCG Combination Therapy
  • Novel Immunotherapy Approaches
  • Disease-Free Survival Studies

Examining alternative treatment options including natural compounds for bladder cancer management.

02 Hematologic Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict therapeutic outcomes. Studies focus on optimizing hydroxyurea treatment protocols.

  • AI-Driven Treatment Prediction
  • Drug Resistance Analysis
  • Personalized Medicine Approaches

Integration of machine learning technologies to enhance treatment effectiveness.

03 Prostate Cancer Research

Comparative studies evaluating different dosing regimens for metastatic prostate cancer treatments, focusing on optimizing therapeutic combinations while minimizing adverse effects.

  • Treatment Safety Profiles
  • Dosing Schedule Optimization
  • Combination Therapy Assessment

Investigating innovative approaches to enhance treatment tolerability and effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.